Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (Diluted Average) (2022 - 2025)

Dianthus Therapeutics has reported Shares Outstanding (Diluted Average) over the past 4 years, most recently at $37.8 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $37.8 million for Q3 2025, up 10.39% from a year ago — trailing twelve months through Sep 2025 was $37.8 million (up 10.39% YoY), and the annual figure for FY2024 was $33.3 million, up 546.44%.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $37.8 million at Dianthus Therapeutics, up from $35.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for DNTH hit a ceiling of $58.8 million in Q2 2022 and a floor of $874138.0 in Q3 2022.
  • Median Shares Outstanding (Diluted Average) over the past 4 years was $33.3 million (2024), compared with a mean of $24.3 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): tumbled 98.51% in 2023 and later soared 3812.11% in 2024.
  • Dianthus Therapeutics' Shares Outstanding (Diluted Average) stood at $874234.0 in 2022, then skyrocketed by 489.48% to $5.2 million in 2023, then soared by 546.44% to $33.3 million in 2024, then grew by 13.45% to $37.8 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $37.8 million (Q3 2025), $35.8 million (Q2 2025), and $35.8 million (Q1 2025) per Business Quant data.